NCT01456130 - Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogues in Type 2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

Diabetes Mellitus

Interventions

DRUG

Alogliptin

Alogliptin tablets

DRUG

Rapid-acting insulin secretagogue

Either of the following commercially available rapid-acting insulin secretagogues as prescribed by the Investigator: (i) Nateglinide: Dose: 30 mg tablet or 90 mg tablet (ii) Mitiglinide calcium hydrate: Dose: 5 mg tablet or 10 mg tablet

Trial Locations (14)

Unknown

Nagoya

Fukuoka

Kurume-shi

Sapporo

Kobe

Kagoshima

Kumamoto

Osaki-shi

Minou-shi

Osaka

Kamio-shi

Koshigaya-shi

Adachi-ku

Chuo-ku